Introduction
============

Cilioretinal artery occlusion involving the macula typically causes a sudden catastrophic loss of vision and subsequent destruction of inner retinal neurons. Cilioretinal artery occlusion has no established effective treatment. Hopeful observation might best characterize the ophthalmologists' recommendations to the stricken patients.[@b1-imcrj-9-029]

An 83-year-old Caucasian female sustained a sudden loss of vision in her left eye 2 hours after a cardiac catheterization before resuming her customary anticoagulant for atrial fibrillation. For 24 hours, there was a progressive decline in central vision that began to reverse after beginning a new medical food developed for addressing retinal ischemia associated with the common dysfunctional polymorphism of the gene methylenetetrahydrofolate reductase (*MTHFR*) *C677T*, which interferes with retinal folate metabolism.

After 4 months, her vision had improved from 20/80 to 20/40, and optical coherence tomography (OCT) scanning showed unexpected preservation of the inner retinal neurons compared to other published cases.

Retinal ischemia is the final common pathway for many vascular retinopathies causing vision loss. The ability of clinicians to reduce ischemia has a profound effect on structural preservation and vision preservation.

Case presentation
=================

A concerned cardiologist recently requested an urgent consultation for one of his patients who had experienced a loss of vision 2 hours after an uneventful cardiac catheterization. Prior to her catheterization, she had been taken off blood thinners, prescribed for atrial fibrillation. The cardiologist was informed about this 24 hours after the vision loss, and immediately requested ophthalmologic consult on an emergency basis. She was examined by the author (CJB), an ophthalmologist, later that same day.

The patient was an 83-year-old Caucasian female of European descent, who was in moderate distress. She noted that after the catheterization, she had been fine for 2 hours, but as she prepared to leave the hospital, her left eye suddenly developed a lavender central blind spot, which over the next 24 hours progressed to a dark smoky blue scotoma with complete loss of vision within the scotoma.

She had a history of cataract, amaurosis fugax, labile hypertension, and atrial fibrillation for which she ordinarily took lisinopril and warfarin. In preparation for her cardiac catheterization, she had discontinued her warfarin for several days. She had now resumed it. Her sedimentation rate was 20.0, Westergren method, and her C-reactive protein was 0.8. She had no history, signs, or symptoms suggestive of temporal arteritis or giant cell arteritis.

On examination, the patient's best visual acuity in her left eye (VA OS \[oculus sinister\]) was 20/80, and she had a cilioretinal artery occlusion with edema involving the maculopapular bundle and macula of the left eye, which was documented photographically, albeit through a moderately dense cataract ([Figure 1A](#f1-imcrj-9-029){ref-type="fig"}). There was no associated central vein occlusion.

She related that her vision had declined steadily since the initial event. At first, she could still see a cloudy image, but now there was a dark purple cloud getting denser and denser. She feared further permanent vision loss was imminent.

Faced with a 24-hour-old progressive nonarteritic ischemic infarct of the macular region where there was little established effective therapy to recommend, she was offered Ocufolin™ (Global Healthcare Focus, LLC, Montgomery, AL, USA), a new medical food developed to address retinal ischemia and associated oxidative stress. She accepted and took one capsule daily for 5 weeks.

After 5 weeks, her VA OS corrected to 20/40. She stated that she could see through a faint residual lavender cloud, enough for most activities except reading. She also stated that there was ongoing steady improvement, which began a few hours after beginning Ocufolin™. Examination revealed resolution of retinal edema with some dependent retinal exudate and mild temporal optic nerve pallor. At this time, her dosage was advanced to two capsules Ocufolin™ daily.

After 3 months, her best VA OS remained 20/40, and the subjective purple haze was much diminished. She was able to perform all normal functions with the left eye, except those requiring fine resolution ([Figure 1B](#f1-imcrj-9-029){ref-type="fig"}).

After 4 months, she reported continued visual improvement subjectively. An OCT scan demonstrated a narrow line of macular thinning corresponding to the central zone of the cilioretinal artery occlusion, but with substantial preservation on either side of it ([Figure 2](#f2-imcrj-9-029){ref-type="fig"}). Cross-sectional imaging showed surprising preservation of the ganglion cell layer and inner nuclear layer, considering that more than 24 hours had elapsed before addressing the retinal ischemia ([Figure 3](#f3-imcrj-9-029){ref-type="fig"}). After 8 months her vision recovered to 20/25 with a small paracentral scotoma.

Testing revealed she carried the common *MTHFR C677T* genotype, which decreases methylation of folate and increases oxidative stress and ischemic events.[@b2-imcrj-9-029]--[@b4-imcrj-9-029]

She had better vision, less ganglion cell loss, and less visible optic nerve pallor than would be expected at that point. She continues to be under observation taking the Ocufolin™. The Washington Regional Institutional Review Board advised that this case report did not require approval for publication; written informed consent was obtained from the patient.

Discussion
==========

The incidence of retinal artery embolism detectable immediately after cardiac catheterization has been reported to be between 2% and 6%. Despite such a high frequency of retinal embolism, they are rarely noticed and vision is rarely affected. Cilioretinal artery occlusion is an uncommon form of retinal artery occlusion and rarely is a complication of coronary artery catheterization.[@b5-imcrj-9-029]--[@b9-imcrj-9-029]

A patient who has lost vision due to a retinal artery occlusion in the postacute phase has few options to protect the retina and restore functional vision. After investigation for causation, initiation of blood thinners and perhaps hyperbaric oxygen therapy, there is nothing left for an eye specialist to do except wait with the patient in a hopeful attitude.[@b6-imcrj-9-029],[@b10-imcrj-9-029]--[@b13-imcrj-9-029]

Brown and Shields[@b5-imcrj-9-029] published a series of 187 retinal artery occlusions. Only 5% were cilioretinal artery occlusions. Cella and Avila[@b14-imcrj-9-029] published a two-case report from Brazil wherein the OCT of a branch retinal artery occlusion (BRAO) showed near complete retinal atrophy of the macula. Parcero et al[@b15-imcrj-9-029] published a similar case report of BRAO, also from Brazil. Both Cella and Avila[@b14-imcrj-9-029] and Parcero et al[@b15-imcrj-9-029] demonstrated that retinal artery occlusion featured advanced loss of the ganglion cell and inner nuclear layers. Hayreh et al[@b16-imcrj-9-029] showed, in elderly hypertensive monkeys, that a central retinal artery occlusion (CRAO) of up to 97 minutes showed no permanent damage, but beyond 4 hours resulted in massive irreversible damage to the ganglion cell and inner nuclear layer.

Saxena et al[@b17-imcrj-9-029] reported a case of CRAO with retinal thickness measurements on days 3, 7, 30, and 90. An edematous increase in retinal thickness was noted on day 3. On day 7, there was a marked retinal thickness decrease suggesting retinal reperfusion injury. Retinal thickness returned to normal on day 30, and retinal atrophy was noted on day 90. They propose that reperfusion around day 7 might, as in other tissues, be associated with reperfusion injury and eventual retinal atrophy. This suggests that there might be a window for prevention of retinal perfusion injury before day 7, which might prevent retinal atrophy at day 90.[@b17-imcrj-9-029]

Mason et al[@b18-imcrj-9-029] reported on a series of 54 BRAO patients, showing that initial acuity was the best predictor of final acuity. Only 14% of patients initially 20/100 or worse returned to 20/40.[@b18-imcrj-9-029]

Kreis et al[@b7-imcrj-9-029] reported on 100 patients undergoing cardiac catheterization with preprocedural and postprocedural retinal imaging. They found 2% of the patients had new retinal emboli in the right superior temporal retinal arterioles. None of them had vision loss. Kojuri et al[@b8-imcrj-9-029] reported on 300 patients, with 6% having retinal emboli. Only one of the 300 experienced symptoms.[@b7-imcrj-9-029],[@b8-imcrj-9-029]

Recently, a personalized medical food, Ocufolin™, has been developed for addressing the underlying issues of genetically dysfunctional folate metabolism and the resultant increased oxidative stress complicating retinal ischemia.

Ocufolin™ specifically addresses the ischemic consequences of the C677T polymorphism of the *MTHFR* gene, which is present in 40% of the Caucasian American population, 50% of Europeans (UK), 50% of Latin Americans, and a lower percentage in African-Americans and Asian-Americans.[@b19-imcrj-9-029]--[@b23-imcrj-9-029]

The C677T polymorphism has been linked to several other retinal ischemic conditions, including hypertensive retinopathy, thrombophilic retinal artery occlusion as well as branch and CRAOs, ischemic cerebral stroke, and small vessel disease.[@b2-imcrj-9-029],[@b24-imcrj-9-029]--[@b31-imcrj-9-029]

The C677T polymorphism results in an impaired ability to produce plasma L-methylfolate due to an impaired sensitivity to riboflavin (vitamin B2). L-methylfolate is the active form of folate and essential to cellular homeostasis and tissue repair. *MTHFR C677T* is associated with elevated blood pressure and elevated homocysteine, which are both known to damage small vessels. The downstream consequences of this are seen as increased cardiovascular disease and increased small vessel disease of the central nervous system, especially the retina. Increased oxidative stress, homocysteine, and inflammation are causes of arterial and venous occlusive disease with concomitant capillary dropout, damage to ganglion cells, bipolar cells, and photoreceptors; all of which are cascading effects caused by limited perfusion of cells that natively have very high metabolic activity.[@b3-imcrj-9-029],[@b32-imcrj-9-029]--[@b34-imcrj-9-029]

Patients with the dysfunctional allele *MTHFR C677T* are more likely to develop hyperhomocysteinemia, neurovascular small vessel disease of the central nervous system, ischemia, and stroke.[@b4-imcrj-9-029]

Retinal ischemia can be addressed by optimizing specific micronutrients that lower homocysteine and promote glutathione. Additionally, homocysteine is directly toxic to retinal ganglion cells and photoreceptors, so lowering homocysteine is essential.[@b35-imcrj-9-029]--[@b37-imcrj-9-029]

Ocufolin™ incorporates L-methylfolate (Metafolin^®^, Merck KGaA, Darmstadt, Germany), B2 (riboflavin), B6, and methyl B12. Riboflavin promotes the methylation of tetrahydrofolate ultimately yielding L-methylfolate. L-methylfolate and methyl B12 act to increase the methylation of homocysteine, thus converting it to methionine. Ocufolin™ additionally contains vitamin C, vitamin D, selenium, zinc, copper, lutein, and zeaxanthin that recycle spent glutathione, as well as *n*-acetyl cysteine (NAC). NAC is a glutathione precursor that readily crosses the blood/brain and blood/retinal barriers. Under ischemic conditions, it has an antiapoptotic effect on neurons of the brain and retinal ganglion cells and retinal pigment epithelium. NAC and thiamin have been shown to be neuroprotective to the brain and retina under ischemic conditions by reducing oxidative stress in the small vessels and retinal tissues. In particular, it might be most effective if initiated prior to the reperfusion stage occurring between the third and seventh day.[@b38-imcrj-9-029]--[@b43-imcrj-9-029]

In addition, systemic hypertension can be a result of hyperhomocysteinemia associated with the *MTHFR C677T* polymorphism and may be mitigated by folate supplementation.[@b44-imcrj-9-029]

A single case report is not proof of concept, but the patient's experience is supportive. She began improving within hours after her first dose of Ocufolin™, and she continued to improve steadily for at least 8 months, returning to 20/25 vision with a small central scotoma. Significantly better than expected preservation of all layers of the retina and its architecture was noted at 4 months, in contrast to the patients reported by Cella and Avila,[@b14-imcrj-9-029] Parcero et al,[@b15-imcrj-9-029] or the monkey subjects of Hayreh et al.[@b16-imcrj-9-029]

A specific supplementation with selected micronutrients designed for the ischemic consequences of the *MTHFR C677T* polymorphism might be an interesting new approach, particularly for patients with that common inborn error of metabolism, which affects a large percentage of patients with European and Latin American heritage. Ideally, it would be started as near to the onset as possible; however, our patient experienced the benefits of increased visual acuity and remarkable neuroprotection despite waiting over 24 hours to address the situation.

Conclusion
==========

Our case, in a patient with the common *MTHFR C677T* polymorphism, contrasts with previous case reports of retinal artery occlusion. This patient had better recovery of vision, and better than expected preservation of the inner retinal layers of the nasal macula, especially the ganglion cell layer, possibly due to protection from ischemia by NAC and other ingredients addressing downstream effects of genetic methylation impairment.

It is conceivable that better results could have occurred with earlier intervention. Nonetheless, her improvement is remarkable. The use of Ocufolin™, a new medical food designed to address the ischemic consequences of this common inborn error of metabolism, appears to have been successful in this case. A proper trial of this approach is to be hoped for in the future.
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![(**A**) shows acute cilioretinal artery occlusion after 24 hours following cardiac catheterization. (**B**) shows resolution of the retinal edema, and residual retinal exudates, 14 weeks later.\
**Notes:** Note deep retinal edema extending into the fovea of the left eye. Present also is a choroidal nevus of the macula.](imcrj-9-029Fig1){#f1-imcrj-9-029}

![OCT scan of retina in cross-section showing loss of RPE and deep retinal structures nasal to the fovea 14 weeks after the occlusion.\
**Abbreviations:** OCT, optical coherence tomography; RPE, retinal pigment epithelium.](imcrj-9-029Fig2){#f2-imcrj-9-029}

![OCT scan of the macula showing loss of retinal pigment epithelium 14 weeks after the occlusion.\
**Abbreviations:** OS, oculus sinister; ILM, internal limiting membrane; RPE, retinal pigment epithelium; OCT, optical coherence tomography.](imcrj-9-029Fig3){#f3-imcrj-9-029}
